Compare Stocks: RGC, AXSM, RDY, and CRNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$199.02 -3.5%	$227.43	$112.90 ▼ $260.19	$10.42B	0.65	694,855 shs	441,177 shs
CRNX Crinetics Pharmaceuticals	$84.84 0.0%	$73.98	$30.25 ▼ $84.89	$9.00B	0.12	2.28 million shs	1.13 million shs
RDY Dr. Reddy's Laboratories	$12.17 +0.1%	$12.86	$11.36 ▼ $15.67	$10.17B	0.29	2.43 million shs	1.67 million shs
RGC Regencell Bioscience	$5.50 -0.4%	$6.01	$4.51 ▼ $69.00	$2.72B	1.88	174,824 shs	73,381 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-3.51%	-4.21%	-12.49%	-15.12%	+63.32%
CRNX Crinetics Pharmaceuticals	-0.01%	+0.18%	+1.14%	+138.65%	+179.08%
RDY Dr. Reddy's Laboratories	+0.12%	-0.16%	+3.35%	-10.81%	-14.51%
RGC Regencell Bioscience	-0.36%	+3.77%	-2.65%	-76.99%	-61.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$199.02 -3.5%	$227.43	$112.90 ▼ $260.19	$10.42B	0.65	694,855 shs	441,177 shs
CRNX Crinetics Pharmaceuticals	$84.84 0.0%	$73.98	$30.25 ▼ $84.89	$9.00B	0.12	2.28 million shs	1.13 million shs
RDY Dr. Reddy's Laboratories	$12.17 +0.1%	$12.86	$11.36 ▼ $15.67	$10.17B	0.29	2.43 million shs	1.67 million shs
RGC Regencell Bioscience	$5.50 -0.4%	$6.01	$4.51 ▼ $69.00	$2.72B	1.88	174,824 shs	73,381 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-3.51%	-4.21%	-12.49%	-15.12%	+63.32%
CRNX Crinetics Pharmaceuticals	-0.01%	+0.18%	+1.14%	+138.65%	+179.08%
RDY Dr. Reddy's Laboratories	+0.12%	-0.16%	+3.35%	-10.81%	-14.51%
RGC Regencell Bioscience	-0.36%	+3.77%	-2.65%	-76.99%	-61.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.91	Moderate Buy	$267.60	34.46% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.53% Downside
RDY Dr. Reddy's Laboratories	1.50	Reduce	N/A	N/A
RGC Regencell Bioscience	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RGC, AXSM, RDY, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$306.00 ➝ $316.00
8/11/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$304.00 ➝ $297.00
8/11/2026	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$242.00 ➝ $251.00
8/11/2026	AXSM Axsome Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$260.00 ➝ $275.00
8/11/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy ➝ Market Perform
8/11/2026	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$255.00 ➝ $256.00
8/11/2026	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$267.00 ➝ $268.00
7/28/2026	CRNX Crinetics Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$55.00 ➝ $85.00

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$638.50M	16.33	N/A	N/A	$1.59 per share	125.17
CRNX Crinetics Pharmaceuticals	$7.70M	1,168.70	N/A	N/A	$11.24 per share	7.55
RDY Dr. Reddy's Laboratories	$3.58B	2.84	$0.85 per share	14.38	$4.90 per share	2.48
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	49.02	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.44	27.66	21.35	2.55	10.15%	9.49%	6.32%	10/23/2026 (Estimated)
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RGC, AXSM, RDY, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.49%	+6.96%	13.64%	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.52	1.43	1.34
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39
RGC Regencell Bioscience	N/A	1.41	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CRNX Crinetics Pharmaceuticals	98.51%
RDY Dr. Reddy's Laboratories	3.85%
RGC Regencell Bioscience	0.13%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
CRNX Crinetics Pharmaceuticals	3.80%
RDY Dr. Reddy's Laboratories	2.00%
RGC Regencell Bioscience	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	52.38 million	41.59 million	Optionable
CRNX Crinetics Pharmaceuticals	210	106.07 million	102.04 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.97 million	Optionable
RGC Regencell Bioscience	10	494.49 million	484.60 million	N/A

RGC, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

RGC Resources: More Likely To Appeal More To Income-Focused Investors

August 18, 2026 | seekingalpha.com

Regencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-K

July 3, 2026 | theglobeandmail.com

Regencell Bioscience surges on apparent short squeeze

July 1, 2026 | msn.com

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Investors Have Until June 23, 2026 to Seek a Leadership Role in the Securities Class Action Lawsuit Contact Kaplan Fox ...

June 30, 2026 | theglobeandmail.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

June 23, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 23, 2026 | prnewswire.com

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

June 23, 2026 | businesswire.com

Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors

June 23, 2026 | globenewswire.com

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

June 23, 2026 | prnewswire.com

RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

June 23, 2026 | tmcnet.com

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

June 23, 2026 | prnewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | tmcnet.com

REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

June 22, 2026 | globenewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC)Â Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | businesswire.com

DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

June 22, 2026 | globenewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC

June 22, 2026 | globenewswire.com

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited ...

June 21, 2026 | gazettextra.comG

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC

June 21, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 21, 2026 | globenewswire.com

RGC DEADLINE: The Gross Law Firm Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline

June 19, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC, AXSM, RDY, and CRNX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$199.02 -7.25 (-3.51%)

As of 08/28/2026 04:00 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.84 -0.01 (-0.01%)

As of 08/28/2026 04:00 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Dr. Reddy's Laboratories NYSE:RDY

$12.17 +0.01 (+0.08%)

As of 08/28/2026 03:58 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Regencell Bioscience NASDAQ:RGC

$5.50 -0.02 (-0.36%)

As of 08/28/2026 04:00 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGC, AXSM, RDY, and CRNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGC, AXSM, RDY, and CRNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGC, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC, AXSM, RDY, and CRNX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Crinetics Pharmaceuticals NASDAQ:CRNX

Dr. Reddy's Laboratories NYSE:RDY

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGC, AXSM, RDY, and CRNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGC, AXSM, RDY, and CRNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGC, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC, AXSM, RDY, and CRNX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Crinetics Pharmaceuticals NASDAQ:CRNX

Dr. Reddy's Laboratories NYSE:RDY

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools